ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Any Fixed Combination Therapy

First Posted Date: 2012-07-11

Last Posted Date: 2012-09-21

Lead Sponsor: Allergan

Target Recruit Count: 4385

Registration Number: NCT01637246

Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale

Completed

Conditions: Rosacea
Erythema

Interventions: Drug: No Intervention

First Posted Date: 2012-07-10

Last Posted Date: 2019-11-18

Lead Sponsor: Allergan

Target Recruit Count: 104

Registration Number: NCT01636765

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Phase 2

Completed

Conditions: Meibomian Gland Dysfunction

Interventions: Drug: AGN-195263 0.1%
Drug: AGN-195263 0.03%
Drug: AGN-195263 0.01%
Drug: AGN-195263 Vehicle

First Posted Date: 2012-07-04

Last Posted Date: 2017-09-08

Lead Sponsor: Allergan

Target Recruit Count: 232

Registration Number: NCT01633788

Locations: 🇺🇸
Virginia Eye Consultants, Norfolk, Virginia, United States
🇺🇸
Ophthalmic Consultants Long Island, Rockville Centre, New York, United States
🇺🇸
Wohl Eye Center, Bloomingdale, Illinois, United States

and more 30 locations

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%

First Posted Date: 2012-07-03

Last Posted Date: 2012-09-21

Lead Sponsor: Allergan

Target Recruit Count: 10337

Registration Number: NCT01632423

A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years

Completed

Conditions: Glaucoma, Open-Angle

Interventions: Other: Standard of Care

First Posted Date: 2012-06-27

Last Posted Date: 2013-06-20

Lead Sponsor: Allergan

Target Recruit Count: 315

Registration Number: NCT01629407

GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Fixed combination 0.3 mg bimatoprost and 5 mg timolol

First Posted Date: 2012-06-27

Last Posted Date: 2012-09-24

Lead Sponsor: Allergan

Target Recruit Count: 392

Registration Number: NCT01628601

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%

First Posted Date: 2012-06-27

Last Posted Date: 2012-09-24

Lead Sponsor: Allergan

Target Recruit Count: 854

Registration Number: NCT01628588

A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Other: Standard of Care

First Posted Date: 2012-06-27

Last Posted Date: 2012-09-05

Lead Sponsor: Allergan

Target Recruit Count: 4812

Registration Number: NCT01628614

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost 0.03%

First Posted Date: 2012-06-20

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 585

Registration Number: NCT01623479

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: dexamethasone intravitreal implant

First Posted Date: 2012-06-13

Last Posted Date: 2016-03-14

Lead Sponsor: Allergan

Target Recruit Count: 375

Registration Number: NCT01618266

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy